Register of
Medicinal Products

Product class: Medicinal product with marketing authorization
Medicinal product class: Human medicine
Name of medicinal product: BAQSIMI
Active substances:
Estonian, English, Latin
ATC code: H04AA01
Dosage form: nasal powder in single-dose container
Strength: 3mg
Legal status for supply*: Subject to medicinal prescription
Summary of product characteristics (SPC):
Package information leaflet (PIL): EST
Indication: Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.
Safety features: Yes
Marketing authorization holder: Eli Lilly Nederland B.V. 
Marketing authorization number: EU/1/19/1406 
Marketing authorization issued on: December 16, 2019 
Marketing authorization expires on: December 18, 2024 
Marketing authorization procedure type: Centralised 
Assessment report:   
Package code Name of medicinal product Dosage form Package Legal status Reimbursements Reference price Last imported PƤritolumaa Additional information
1809176  BAQSIMI  nasal powder in single-dose container  3mg 1TK  Prescription           
1809187  BAQSIMI  nasal powder in single-dose container  3mg 2TK  Prescription           
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription

You can download Acrobat Reader fromhere